Indications
Pavblu is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
Composition
- Active substance
- aflibercept
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pavblu
- Active substance
- aflibercept
- ATC code
- S01LA05
- Group
- Sensory organs
- Therapeutic area
- Wet Macular Degeneration, Macular Edema, Retinal Vein Occlusion, Choroidal Neovascularization, Diabetes Complications